

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Azelnidipine

March 17, 2026

Therapeutic category

Antihypertensives

Non-proprietary name

Azelnidipine

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
 This English version is intended to be a reference material to provide convenience for users.
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current	Revision								
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Itraconazole, miconazole (oral dosage form, injections, agents for oral use), fluconazole, fosfluconazole, voriconazole, posaconazole, HIV protease inhibitors (preparations containing ritonavir, atazanavir sulfate, fosamprenavir calcium hydrate, preparations containing darunavir), preparations containing cobicistat, nirmatrelvir/ritonavir, ensitrelvir fumaric acid</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <p>(N/A)</p>	<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Itraconazole, miconazole (oral dosage form, injections, agents for oral use), fluconazole, fosfluconazole, voriconazole, posaconazole, HIV protease inhibitors (preparations containing ritonavir, atazanavir sulfate, fosamprenavir calcium hydrate, preparations containing darunavir), preparations containing cobicistat, nirmatrelvir/ritonavir, ensitrelvir fumaric acid, <u>clarithromycin, ceritinib</u></p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <table border="1" data-bbox="1133 970 2000 1361"> <thead> <tr> <th data-bbox="1133 970 1473 1070">Drugs</th> <th data-bbox="1473 970 1738 1070">Signs, symptoms, and treatment</th> <th data-bbox="1738 970 2000 1070">Mechanism/risk factors</th> </tr> </thead> <tbody> <tr> <td data-bbox="1133 1070 1473 1361"> <u>Clarithromycin</u> <u>Ceritinib</u> </td> <td data-bbox="1473 1070 1738 1361"> <u>The effects of azelnidipine may be enhanced.</u> </td> <td data-bbox="1738 1070 2000 1361"> <u>It is considered that these drugs inhibit CYP3A4 and that the clearance of azelnidipine is decreased.</u> </td> </tr> </tbody> </table>			Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	<u>Clarithromycin</u> <u>Ceritinib</u>	<u>The effects of azelnidipine may be enhanced.</u>	<u>It is considered that these drugs inhibit CYP3A4 and that the clearance of azelnidipine is decreased.</u>
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors							
<u>Clarithromycin</u> <u>Ceritinib</u>	<u>The effects of azelnidipine may be enhanced.</u>	<u>It is considered that these drugs inhibit CYP3A4 and that the clearance of azelnidipine is decreased.</u>							

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.